Company Q BioMed Inc. Other OTC
Equities
QBIO
US74736N1054
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Biomedical
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +45.38% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +45.38% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Denis Corin
CEO | Chief Executive Officer | 51 | 21/15/21 |
Ari Jatwes
DFI | Director of Finance/CFO | - | - |
Director/Board Member | 55 | 01/15/01 | |
Keith Pinder
IRC | Investor Relations Contact | - | - |
Robert Derham
PRN | Corporate Officer/Principal | - | - |
Geoff Fatzinger
LAW | General Counsel | - | 31/20/31 |
Corporate Officer/Principal | 70 | 16/15/16 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 55 | 01/15/01 | |
Denis Corin
CEO | Chief Executive Officer | 51 | 21/15/21 |
Rick Panicucci
BRD | Director/Board Member | 63 | 13/18/13 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,000,000 | 0 | 0 | 97.01 % |
Stock B | 0 | 296,000 | 0 | 0 | |
Stock C | 0 | 500,000 | 0 | 272,002 ( 54.40 %) | |
Stock D | 1 | 145,094,531 | 140,760,821 ( 97.01 %) | 0 |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+16.45% | 12TCr | |
+21.96% | 12TCr | |
+25.74% | 2.7TCr | |
-20.05% | 2.04TCr | |
-16.28% | 1.59TCr | |
-15.94% | 1.64TCr | |
-44.35% | 1.56TCr | |
+63.91% | 1.49TCr | |
+2.52% | 1.36TCr |